Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.66 |
| ▸ | NPC1 | O15118 | 5/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13922829 | 0.99 | RAB9A (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9093258 | 0.94 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL13922820 | 0.88 | RAB9A (0.64) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL9664553 | 0.85 | RAB9A (0.69) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL25131761 | 0.85 | RAB9A (0.58) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL28838794 | 0.84 | NPC1 (0.63) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL12643417 | 0.83 | DEGS1 (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1DEGS1 | |
| SCHEMBL1527301 | 0.82 | NPC1 (0.52) | RAB9ANPC1SMN1; SMN2ALDH1A1DEGS1 | |
| SCHEMBL8240613 | 0.82 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 | |
| SCHEMBL13922914 | 0.82 | RAB9A (0.59) | RAB9ANPC1SMN1; SMN2ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| WO-2016094226-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GLYCOREGIMMUNE, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | ALTIUM GROWTH FUND, LP | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160158258-A1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | RXRA, RXRG, CX3CR1 | RAB9A 3510/4885NPC1 2561/4885SMN1; SMN2 623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.